JNJ Johnson & Johnson

140.97
+0.59  (+0%)
Previous Close 140.38
Open 141.25
52 Week Low 109.16
52 Week High 157
Market Cap $371,646,576,542
Shares 2,636,352,249
Float 2,634,818,148
Enterprise Value $379,650,128,714
Volume 5,152,238
Av. Daily Volume 7,646,881
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Ad26.COV2-S
COVID-19 coronavirus vaccine
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Guselkumab (NOVA)
Hidradenitis Suppurativa
Phase 2
Phase 2
Phase 2 trial initiation announced November 19, 2018.
Erdafitinib
Urothelial cancer
Approved
Approved
FDA Approval announced April 12, 2019.
Niraparib (Galahad)
Castration-Resistant Prostate Cancer
Phase 2
Phase 2
Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Phase 3
Phase 3
Phase 3 trial met primary endpoint - May 28, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Approved
Approved
FDA Approval announced May 1, 2020.
IMBRUVICA (ibrutinib) and rituximab
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Approved
Approved
FDA Approval announced April 21, 2020.
Ponesimod
Relapsing multiple sclerosis
NDA Filing
NDA Filing
NDA filing announced March 18, 2020.
Bermekimab
Systemic Sclerosis
Phase 2
Phase 2
Phase 2 commencement of enrolment announced October 2, 2019.
Bermekimab
Atopic Dermatitis (AD)
Phase 2
Phase 2
Phase 2 commencement of enrolment announced November 12, 2019.
Bermekimab
Hidradenitis Suppurativa (HS)
Phase 2
Phase 2
Phase 2 commencement of enrolment announced October 23, 2019.
Dolutegravir + rilpivirine
HIV
CRL
CRL
Complete Response Letter issued December 21, 2019.
STELARA (USTEKINUMAB)
Ulcerative colitis
Approved
Approved
FDA Approval announced October 21, 2019.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Approved
Approved
FDA approval announced October 14, 2019.
STELARA (USTEKINUMAB)
Plaque psoriasis - pediatric
sNDA Filing
sNDA Filing
sBLA filing announced October 7, 2019.
Esketamine
Major depressive disorder (MDD)
sNDA Filing
sNDA Filing
sNDA filing announced October 2, 2019.
INVOKANA - CREDENCE
Diabetic Kidney Disease
Approved
Approved
FDA Approval announced September 30, 2019.
Daratumumab + VTD
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
Approved
Approved
FDA Approval announced September 26, 2019.
Apalutamide
Metastatic castration-sensitive prostate cancer (mCSPC).
Approved
Approved
FDA Approval announced September 18, 2019.
Guselkumab
Psoriatic Arthritis
sNDA Filing
sNDA Filing
sBLA filing announced September 16, 2019.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
Approved
Approved
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
Approved
Approved
FDA Approval announced June 28, 2019.
Guselkumab vs Cosentyx - ECLIPSE
Psoriasis
Phase 3
Phase 3
Phase 3 primary endpoint met - December 12, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 2/3
Phase 2/3
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab
Ulcerative colitis
Phase 2
Phase 2
Phase 2a initiation announced January 17, 2019.
Esketamine
Treatment resistant depression
Approved
Approved
FDA approval announced March 5, 2019.
Guselkumab
Plaque psoriasis
Approved
Approved
Approval announced February 27, 2019.
Apalutamide
Non-metastatic castration-resistant prostate cancer (CRPC)
Approved
Approved
Approval announced February 14, 2018.
INVOKANA CANVAS
Type 2 diabetes
Approved
Approved
FDA Approval announced October 30, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Approved
Approved
FDA approval announced August 27, 2018.
D/C/F/TAF
HIV
Approved
Approved
FDA Approval announced July 17, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Atabecestat
Alzheimer’s disease
Phase 2
Phase 2
Announced May 18, 2018 that dosing will be stopped.
DARZALEX (Daratumumab) - ALCYONE
Frontline multiple myeloma (non-transplant)
Approved
Approved
Approval announced May 7, 2018.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
Approved
Approved
sNDA approval announced February 8, 2018.
SIMPONI ARIA
Ankylosing Spondylitis
Approved
Approved
Approval announced October 20, 2017.
Imbruvica
Marginal zone lymphoma
Approved
Approved
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
STELARA (USTEKINUMAB)
Plaque psoriasis
Approved
Approved
Approval announced October 13, 2017.
Sirukumab
Rheumatoid arthritis
CRL
CRL
CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
Guselkumab
Plaque psoriasis
Approved
Approved
Approval announced July 13, 2017.
SIMPONI ARIA
Psoriatic arthritis (PsA)
Approved
Approved
Approval announced October 20, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
Phase 3
Phase 3
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Approved
Approved
Approval announced August 2, 2017.
Talacotuzumab
Acute myeloid leukemia (AML)
Phase 3
Phase 3
Phase 3 discontinuation announced October 17, 2017.

Latest News

  1. Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Ray Jordan has joined Moderna as Chief Corporate Affairs Officer, effective Monday, June 15, 2020. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel.

    "It has been a pleasure working with Ray on a consulting basis over the last four months and I am thrilled to welcome him as our Chief Corporate Affairs Officer and to the Executive Committee," said Stéphane Bancel, Chief Executive Officer of Moderna. "Ray has an impressive track record operating across geographies and at scale at…

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Ray Jordan has joined Moderna as Chief Corporate Affairs Officer, effective Monday, June 15, 2020. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel.

    "It has been a pleasure working with Ray on a consulting basis over the last four months and I am thrilled to welcome him as our Chief Corporate Affairs Officer and to the Executive Committee," said Stéphane Bancel, Chief Executive Officer of Moderna. "Ray has an impressive track record operating across geographies and at scale at Amgen, J&J and Pfizer. His strategic communications and management experience at global commercial biopharmaceutical companies will be a tremendous asset as we continue into late-stage commercial development of our COVID-19 vaccine and our CMV vaccine."

    Mr. Jordan served as Senior Vice President, Corporate Affairs at Amgen (NASDAQ:AMGN) from 2012 through 2019. At Amgen, he was responsible for all internal and external communications, issues management and philanthropy. During his seven-year tenure, he led strategic communications for an unprecedented six product launches. Prior to Amgen, Mr. Jordan spent nine years at Johnson & Johnson (NYSE:JNJ), where he led corporate communications and public affairs for more than 250 operating companies in 60 countries. Previously, Mr. Jordan held a range of positions over the course of 17 years at Pfizer (NYSE:PFE), most recently as Vice President, Communications and Information. He has also served as chair of PhRMA's public affairs section and of the National Pharmaceutical Council's User Group.

    "I've been keenly interested in Moderna's mRNA platform and its potential to build a new class of medicine for years. I've had the privilege of getting to know the executive committee on a consulting basis over the last four months and I am incredibly impressed with the Moderna team and culture. I look forward to building the corporate affairs team and supporting Moderna's mission to bring mRNA medicines and vaccines to patients and populations during this exciting time of growth for the company."

    Mr. Jordan received his Master of Business Administration in marketing and finance from Columbia University and his Bachelor of Arts with concentration in psychology and mathematics from Yale University.

    About Moderna

    Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

    Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).  Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

    View Full Article Hide Full Article
  2. NEW BRUNSWICK, N.J., June 10, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July.

    Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, "Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational…

    NEW BRUNSWICK, N.J., June 10, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July.

    Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, "Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Simultaneously, we are continuing our efforts to build important global partnerships and invest in our vaccine production technology and manufacturing capabilities. Our goal is to ensure we can deliver a vaccine to the world and protect people everywhere from this pandemic."

    The randomized, double-blind, placebo-controlled Phase 1/2a study will evaluate the safety, reactogenicity (response to vaccination), and immunogenicity (immune response) of the investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant in 1045 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older. The study will take place in the U.S. and Belgium.

    The Company is in discussions with the National Institutes of Allergy and Infectious Diseases with the objective to start the Phase 3 SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant, clinical trial ahead of its original schedule, pending outcome of phase 1 studies and approval of regulators.

    As the Company progresses the clinical development of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant, it continues to increase manufacturing capacity and is in active discussions with global partners to ensure worldwide access. The Company committed to the goal of supplying more than one billion doses globally through the course of 2021, provided the vaccine is a safe and effective.

    Johnson & Johnson's efforts to expedite development and production of a SARS-CoV-2 vaccine are enhanced by a collaboration between Janssen and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services.

    COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no approved vaccine for COVID-19.

    For more information on Johnson & Johnson's multi-pronged approach to combatting the pandemic, visit: www.jnj.com/coronavirus.

    About Johnson & Johnson

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

    About the Janssen Pharmaceutical Companies

    At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal.

    Notice to Investors Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive and treatment regimens for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-announces-acceleration-of-its-covid-19-vaccine-candidate-phase-12a-clinical-trial-to-begin-in-second-half-of-july-301073688.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  3. NEW BRUNSWICK, N.J., June 4, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the world's largest and most broadly-based healthcare company, announced today it will host a Health for Humanity investor webcast at 8:00 a.m. Eastern Time on June 18, 2020. The webcast will highlight Johnson & Johnson's 2019 Health for Humanity Report, which documents how Johnson & Johnson is enabling sustainable progress toward the Company's environmental, social and governance (ESG) commitments.

    In addition to key 2019 milestones, the webcast and annual update will include a review of the Company's Health for Humanity 2020 Goals and United Nations Sustainable Development Goals commitment areas, as well as relevant updates related to its COVID-19 efforts. As a…

    NEW BRUNSWICK, N.J., June 4, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the world's largest and most broadly-based healthcare company, announced today it will host a Health for Humanity investor webcast at 8:00 a.m. Eastern Time on June 18, 2020. The webcast will highlight Johnson & Johnson's 2019 Health for Humanity Report, which documents how Johnson & Johnson is enabling sustainable progress toward the Company's environmental, social and governance (ESG) commitments.

    In addition to key 2019 milestones, the webcast and annual update will include a review of the Company's Health for Humanity 2020 Goals and United Nations Sustainable Development Goals commitment areas, as well as relevant updates related to its COVID-19 efforts. As a global healthcare leader, Johnson & Johnson remains committed to mobilizing its deep scientific expertise, extensive partnerships and scalable manufacturing capabilities to address the critical needs of families, communities, healthcare professionals and employees around the world.

    Investors and other interested parties can join this year's Health for Humanity Investor Webcast at 8:00 a.m. Eastern Time on June 18, 2020 by visiting Johnson & Johnson's website, www.investor.jnj.com. To submit a question ahead of the webcast, please send your question to .  A replay will be available at www.investor.jnj.com.

    About the Johnson & Johnson Health for Humanity Report
    Our Johnson & Johnson Health for Humanity Report provides an annual update on performance and progress in ESG areas relevant to our business. The Report details how we are delivering on our commitments in key focus areas of better health for all, responsible business practices and safeguarding the environmental health. The 2019 Health for Humanity Report will be released on June 10, 2020. As part of the Report, the Company is reporting for the first time against the Sustainability Accounting Standards Board (SASB) Standards for all three business segments. The Report  will be available online at http://healthforhumanityreport.jnj.com/ with a 2019 Report Summary also available in English, Spanish, French, Portuguese, Chinese (traditional and simplified), and Japanese.

    About Johnson & Johnson
    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-to-host-annual-health-for-humanity-investor-webcast-301071048.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  4. NEW BRUNSWICK, N.J., May 28, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) will participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 10.   Jennifer Taubert, Executive Vice President, Worldwide Chairman Pharmaceuticals will represent the Company in a session scheduled at 11:20 a.m. (Eastern Time).

    This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

    A webcast and podcast replay will be available approximately two hours after the live webcast.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-to-participate-in-the-goldman-sachs-41st-annual-global-virtual-healthcare-conference-301067227.html

    NEW BRUNSWICK, N.J., May 28, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) will participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 10.   Jennifer Taubert, Executive Vice President, Worldwide Chairman Pharmaceuticals will represent the Company in a session scheduled at 11:20 a.m. (Eastern Time).

    This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

    A webcast and podcast replay will be available approximately two hours after the live webcast.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-to-participate-in-the-goldman-sachs-41st-annual-global-virtual-healthcare-conference-301067227.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  5. HOUSTON, May 19, 2020 /PRNewswire/ -- Mark Lanier, the trial lawyer who earned the largest jury verdict to date on behalf of consumers who have developed cancer from talc-based cosmetics, welcomed an announcement by Johnson & Johnson (NYSE:JNJ) that it would cease manufacturing products containing talc, but he added that more work is ahead for talc victims.

    "We and other trial lawyers and consumer advocates have been sounding the alarm for years," said Mr. Lanier, founder The Lanier Law Firm. "While this is good news for the future health of consumers, it's troubling that J&J still refuses to accept responsibility for a deadly disease affecting tens of thousands of victims. The company's own documents and dozens of peer-reviewed scientific studies…

    HOUSTON, May 19, 2020 /PRNewswire/ -- Mark Lanier, the trial lawyer who earned the largest jury verdict to date on behalf of consumers who have developed cancer from talc-based cosmetics, welcomed an announcement by Johnson & Johnson (NYSE:JNJ) that it would cease manufacturing products containing talc, but he added that more work is ahead for talc victims.

    "We and other trial lawyers and consumer advocates have been sounding the alarm for years," said Mr. Lanier, founder The Lanier Law Firm. "While this is good news for the future health of consumers, it's troubling that J&J still refuses to accept responsibility for a deadly disease affecting tens of thousands of victims. The company's own documents and dozens of peer-reviewed scientific studies have pointed to the connection between Baby Powder and ovarian cancer for decades."

    Citing declining consumer demand and the need to prioritize more "high-demand" products, Johnson & Johnson announced on Tuesday that it would be discontinuing the controversial talc-based Baby Powder in the United States and Canada. The company will continue to sell its remaining inventory as well as a corn starch alternative. 

    In July 2018, a St. Louis jury awarded $4.69 billion to 22 women and their families – represented by The Lanier Law Firm – after finding that decades of daily use of Johnson & Johnson's asbestos-laden talcum powder products caused their ovarian cancer.  

    The six-man, six-woman jury in Judge Rex M. Burlison's 22nd Judicial Circuit Court in St. Louis heard six weeks of testimony and deliberated eight hours before returning a verdict that included $550 million in compensatory damages and $4.14 billion in punitive damages. 

    "We anticipate trying these cases and doing our absolute best to prevail again and again," said Mr. Lanier. "Today's action by the company will stop future exposure, but justice still needs pursuing for those exposed and harmed in the past." 

    The Lanier Law Firm continues to represent clients in claims against Johnson & Johnson. 

    For more than 30 years, the men and women at the Lanier Law Firm have worked tirelessly, throughout the United States, to find unique and effective solutions for their clients. More than 60 skilled attorneys practice law in a broad array of areas, including business litigation, pharmaceutical litigation, asbestos exposure, oil and gas litigation, personal injury, and defective and dangerous products, among others. Named an Elite Trial Law Firm by The National Law Journal, the Lanier Law Firm has offices in Houston, New York, Los Angeles and Oklahoma City. To learn more about Mark Lanier and the Lanier Law Firm, visit http://www.lanierlawfirm.com.  

    Media Contact:  
    J.D. Cargill  
    713-659-5200  
      

    Cision View original content:http://www.prnewswire.com/news-releases/attorney-mark-lanier-gratified-but-not-yet-satisfied-by-johnson--johnson-decision-to-discontinue-talc-based-baby-powder-301062290.html

    SOURCE The Lanier Law Firm

    View Full Article Hide Full Article
View All Johnson & Johnson News